Limits...
Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum.

Li S, Li H, Yang X, Wang W, Huang A, Li J, Qin X, Li F, Lu G, Ding H, Su X, Hou L, Xia W, Shi M, Zhang H, Zhao Q, Dong J, Ge X, Sun L, Bai C, Wang C, Shen X, Fang T, Wang F, Zhang H, Shao N - Oncotarget (2015)

Bottom Line: VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97 cases of normal persons and 129 cases of hepatitis patients.As a membrane protein and/or as free protein, VASN may be an effective target for biological treatment of liver cancer and is a potential biomarker for HCC diagnosis.Small molecular nucleotides targeting VASN are promising biological therapies to HCC.

View Article: PubMed Central - PubMed

Affiliation: Beijing Institute of Basic Medical Sciences, Beijing, China.

ABSTRACT

Unlabelled: We report a new biomarker of hepatocarcinoma, vasorin (VASN), screened by a subtractive EMSA-SELEX strategy from AFP negative serum of hepatocellular carcinoma (HCC) patients with extrahepatic metastases. VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97 cases of normal persons and 129 cases of hepatitis patients. Further validation by Q-PCR,IFA and Western blot showed higher expression of VASN at mRNA and protein levels in HCC cell lines and HCC tissues than in normal controls. RNA interference and forced overexpression assays verified that VASN promotes cell proliferation and migration and inhibits apoptosis. Down-regulation of microRNA miR145 and miR146a is an important mechanism leading to high expression of VASN.

Conclusion: As a membrane protein and/or as free protein, VASN may be an effective target for biological treatment of liver cancer and is a potential biomarker for HCC diagnosis. Small molecular nucleotides targeting VASN are promising biological therapies to HCC.

No MeSH data available.


Related in: MedlinePlus

Forced Overexpression of miR146a downregulated cell growth and migration and increased cell apoptosis through downregulation of VASN expression in HepG2 cells(a) The expression level of VASN mRNA was down regulated after transient transfection of miR146a mimics into HepG2 cells by real-time PCR. (b) The expression level of VASN protein was down regulated after transient transfection of miR146a mimics into HepG2 cells by Western blot. (c) Overexpression of miR146a inhibited HepG2 cell growth by MTS assay. (d) Overexpression of miR146a inhibited HepG2 cell migration by transwell chamber migration assay. (e) Overexpression of miR 146a mimics in HepG2 inhibited migration in a scratch wound assay. Upper: A scratch was created with a 200 μl-pipette tip and photographed. Lower: Photographs at 36h after scratching. (f) Overexpression of miR146a induced HepG2 cell apoptosis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496339&req=5

Figure 6: Forced Overexpression of miR146a downregulated cell growth and migration and increased cell apoptosis through downregulation of VASN expression in HepG2 cells(a) The expression level of VASN mRNA was down regulated after transient transfection of miR146a mimics into HepG2 cells by real-time PCR. (b) The expression level of VASN protein was down regulated after transient transfection of miR146a mimics into HepG2 cells by Western blot. (c) Overexpression of miR146a inhibited HepG2 cell growth by MTS assay. (d) Overexpression of miR146a inhibited HepG2 cell migration by transwell chamber migration assay. (e) Overexpression of miR 146a mimics in HepG2 inhibited migration in a scratch wound assay. Upper: A scratch was created with a 200 μl-pipette tip and photographed. Lower: Photographs at 36h after scratching. (f) Overexpression of miR146a induced HepG2 cell apoptosis.

Mentions: The expression levels of VASN mRNA and protein were down regulated after transient transfection of miR145 and miR146a mimics into HepG2 cells (Figs. 5a, 5b, Figs. 6a, 6b). Cells underwent similar changes as observed in the VASN silencing experiment: cell proliferation was reduced (Fig. 5c, Fig. 6c), cell migration decreased (Figs. 5d, 5e, Figs. 6d, 1e) and apoptosis increased (Fig. 5f, Fig. 6f). Co-transfection of miRNA inhibitors could rescue those phenotypes to a certain degree (Fig. 5, Fig. 6). These results lay the foundation for the application of VASN-targeting nucleic acid drugs such as siRNA, miRNA, and aptamers in future treatment of high-VASN expressing hepatoma.


Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum.

Li S, Li H, Yang X, Wang W, Huang A, Li J, Qin X, Li F, Lu G, Ding H, Su X, Hou L, Xia W, Shi M, Zhang H, Zhao Q, Dong J, Ge X, Sun L, Bai C, Wang C, Shen X, Fang T, Wang F, Zhang H, Shao N - Oncotarget (2015)

Forced Overexpression of miR146a downregulated cell growth and migration and increased cell apoptosis through downregulation of VASN expression in HepG2 cells(a) The expression level of VASN mRNA was down regulated after transient transfection of miR146a mimics into HepG2 cells by real-time PCR. (b) The expression level of VASN protein was down regulated after transient transfection of miR146a mimics into HepG2 cells by Western blot. (c) Overexpression of miR146a inhibited HepG2 cell growth by MTS assay. (d) Overexpression of miR146a inhibited HepG2 cell migration by transwell chamber migration assay. (e) Overexpression of miR 146a mimics in HepG2 inhibited migration in a scratch wound assay. Upper: A scratch was created with a 200 μl-pipette tip and photographed. Lower: Photographs at 36h after scratching. (f) Overexpression of miR146a induced HepG2 cell apoptosis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496339&req=5

Figure 6: Forced Overexpression of miR146a downregulated cell growth and migration and increased cell apoptosis through downregulation of VASN expression in HepG2 cells(a) The expression level of VASN mRNA was down regulated after transient transfection of miR146a mimics into HepG2 cells by real-time PCR. (b) The expression level of VASN protein was down regulated after transient transfection of miR146a mimics into HepG2 cells by Western blot. (c) Overexpression of miR146a inhibited HepG2 cell growth by MTS assay. (d) Overexpression of miR146a inhibited HepG2 cell migration by transwell chamber migration assay. (e) Overexpression of miR 146a mimics in HepG2 inhibited migration in a scratch wound assay. Upper: A scratch was created with a 200 μl-pipette tip and photographed. Lower: Photographs at 36h after scratching. (f) Overexpression of miR146a induced HepG2 cell apoptosis.
Mentions: The expression levels of VASN mRNA and protein were down regulated after transient transfection of miR145 and miR146a mimics into HepG2 cells (Figs. 5a, 5b, Figs. 6a, 6b). Cells underwent similar changes as observed in the VASN silencing experiment: cell proliferation was reduced (Fig. 5c, Fig. 6c), cell migration decreased (Figs. 5d, 5e, Figs. 6d, 1e) and apoptosis increased (Fig. 5f, Fig. 6f). Co-transfection of miRNA inhibitors could rescue those phenotypes to a certain degree (Fig. 5, Fig. 6). These results lay the foundation for the application of VASN-targeting nucleic acid drugs such as siRNA, miRNA, and aptamers in future treatment of high-VASN expressing hepatoma.

Bottom Line: VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97 cases of normal persons and 129 cases of hepatitis patients.As a membrane protein and/or as free protein, VASN may be an effective target for biological treatment of liver cancer and is a potential biomarker for HCC diagnosis.Small molecular nucleotides targeting VASN are promising biological therapies to HCC.

View Article: PubMed Central - PubMed

Affiliation: Beijing Institute of Basic Medical Sciences, Beijing, China.

ABSTRACT

Unlabelled: We report a new biomarker of hepatocarcinoma, vasorin (VASN), screened by a subtractive EMSA-SELEX strategy from AFP negative serum of hepatocellular carcinoma (HCC) patients with extrahepatic metastases. VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97 cases of normal persons and 129 cases of hepatitis patients. Further validation by Q-PCR,IFA and Western blot showed higher expression of VASN at mRNA and protein levels in HCC cell lines and HCC tissues than in normal controls. RNA interference and forced overexpression assays verified that VASN promotes cell proliferation and migration and inhibits apoptosis. Down-regulation of microRNA miR145 and miR146a is an important mechanism leading to high expression of VASN.

Conclusion: As a membrane protein and/or as free protein, VASN may be an effective target for biological treatment of liver cancer and is a potential biomarker for HCC diagnosis. Small molecular nucleotides targeting VASN are promising biological therapies to HCC.

No MeSH data available.


Related in: MedlinePlus